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Abstract
Background: Several models have been designed to predict survival of patients with heart failure. These, while available and
widely used for both stratifying and deciding upon different treatment options on the individual level, have several
limitations. Specifically, some clinical variables that may influence prognosis may have an influence that change over time.
Statistical models that include such characteristic may help in evaluating prognosis. The aim of the present study was to
analyze and quantify the impact of modeling heart failure survival allowing for covariates with time-varying effects known
to be independent predictors of overall mortality in this clinical setting.
Methodology: Survival data from an inception cohort of five hundred patients diagnosed with heart failure functional class
III and IV between 2002 and 2004 and followed-up to 2006 were analyzed by using the proportional hazards Cox model and
variations of the Cox’s model and also of the Aalen’s additive model.
Principal Findings: One-hundred and eighty eight (188) patients died during follow-up. For patients under study, age,
serum sodium, hemoglobin, serum creatinine, and left ventricular ejection fraction were significantly associated with
mortality. Evidence of time-varying effect was suggested for the last three. Both high hemoglobin and high LV ejection
fraction were associated with a reduced risk of dying with a stronger initial effect. High creatinine, associated with an
increased risk of dying, also presented an initial stronger effect. The impact of age and sodium were constant over time.
Conclusions: The current study points to the importance of evaluating covariates with time-varying effects in heart failure
models. The analysis performed suggests that variations of Cox and Aalen models constitute a valuable tool for identifying
these variables. The implementation of covariates with time-varying effects into heart failure prognostication models may
reduce bias and increase the specificity of such models.
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Introduction
Patients with heart failure usually experience a progressive
clinical deterioration over time. Factors that influence the
unfavorable outcome are less predictable over time as they may
be dependent on several, and distinct, factors such as pump failure,
autonomic nervous system influence, cardiac arrhythmias, meta-
bolic derangements (such as renal failure, hyperkalemia, hypoka-
lemia), and complications that many times may be subclinical or
undiagnosed, such as pulmonary embolism. This myriad of
potential complications that may ensue in spite of current therapy
are less predictable over time. Some of them, like progressive
pump failure may be expected to have a more linear downhill
course; others may not.
The incidence and prevalence of heart failure (HF) are rising
worldwide [1]. And although decline trends in HF hospitalization
rates have been shown in Europe [2] and in the USA [3], current
advances in the treatment of both myocardial infarction and heart
failure itself bring the forecast of even higher heart failure
numbers. At the same time, new indications and care for the
transplanted patient is continuously emerging and new ventricular
assist-devices are yearly being introduced into clinical practice
[4,5]. This scenario has brought increasing interest in the
development of new and more sensitive and specific tools for
heart failure prognostication [6].
In fact, a number of different tools for heart failure prognos-
tication already exist and are increasingly being incorporated into
clinical practice [7,8]. These include the Heart Failure Survival
Score [9], the Seattle Heart Failure Model [10], the Organized
Program to Initiate Lifesaving Treatment in Hospitalized Patients
With Heart Failure predictive schemes [11], the Acute Decom-
pensated Heart Failure National Registry regression tree discrim-
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rather different patient populations and analytical tools for model
construction. Some were specifically designed for acute decom-
pensated HF and were not built to be used with out-patient
populations [11,12]. These scores do not rely on survival analysis
for their construction and use different data supposition for their
validity, being specifically tailored for the hospitalized patient with
HF. On the other hand, there are well-established tools for the
out-patient scenario, all of them built in the outline, and
constrains, of survival analysis [9,10]. Although well-designed
and validated, these models do not consider time-varying effects of
their covariates and relied upon the framework of proportional
hazards Cox regression, which assumes proportionality of the
hazards and also that the risk factors act multiplicatively on the
baseline hazard risk function. These assumptions, however, may
not be proper in some applications and there is therefore the need
for alternative models.
Risk factors may also have additive effects instead of multipli-
cative effects in the baseline hazard function. Another typical
deviation from the proportional hazards Cox model is when the
effects of some covariates change with time. For instance, some
risk factors may impose a strong effect right after being recorded,
but gradually lose predictive power (e.g. a treatment effect that is
weakened with time). Models flexible enough to deal with
covariates in which their effects are time-varying are therefore of
great interest in these situations. One of these models is a direct
extension of the proportional hazards Cox model where all or
some effects of the covariates are allowed to change over time [13].
Another is the additive hazards model proposed by Aalen [14–16]
that allows all regression coefficients to vary with time. As,
however, the effect of some of the covariates may change with time
while others not, McKeague and Sasieni [17] suggested a variation
of the Aalen model allowing for this possibility.
Here we have used these models to analyze the survival of
patients diagnosed with heart failure. Our main aim was to explore
the time-varying effect of the different covariates known to be
predictive of mortality in such clinical scenario and highlight the
importance of considering such details in the modeling of heart
failure mortality.
Materials and Methods
Ethics Statement
All patients signed an informed consent form and the study has
been approved by the Ethics Committee of the Heart Institute of
the University of Sao Paulo, Brazil.
Study Sample
Five hundred (500) patients with heart failure in functional class
III or IV of the New York Heart Association were studied. Patients
were included as part of a secondary-cohort of HF individuals
attended at a cardiology tertiary care center in Sao Paulo, Brazil
(Heart Institute of the Sao Paulo University Medical School).
Ascertainment period was from August, 2002 to March, 2004.
The diagnosis of heart failure was made according to previously
published criteria [18,19]. The classification of the etiologies of
heart failure followed previous recommendations [19]. As such,
the diagnosis of chronic heart failure was made through both
clinical and imaging procedures when necessary. Ischemic
cardiomyopathy diagnosis was made when a clear history of
previous myocardial infarction and no other probable cause of
heart dysfunction was present or, alternatively, through coronary
angiography. All patients with the final diagnosis of idiopathic
dilated cardiomyopathy were studied through coronary angiogra-
phy to exclude the diagnosis of ischemic cardiomyopathy. Therapy
was titrated according to the patient’s needs and tolerance by the
physician in charge and included angiotensin-converting enzyme
blockers, angiotensin receptor blockers, diuretics, and beta-blocker
(carvedilol). Carvedilol is the standard beta-blocker prescribed at
the Heart Institute of the Sao Paulo University. Spironolactone
was used only in a very small fraction of patients (probably
reflecting the enrollment period of the cohort).
Beginning of follow-up was defined as enrollment in the
protocol. Follow-up was assessed in the last outpatient medical
visit or by telephone contact. In addition, the mortality database of
Sao Paulo City Authority was also scrutinized to discover patient
deaths (ProAim 2 Programa de Aprimoramento de Informac ¸o ˜es
de Mortalidade do Municı ´pio de Sa ˜o Paulo). For the current
analysis, last follow-up was evaluated in April, 2006. Primary end-
Table 1. Clinical characteristics of the study sample.
Variables Descriptive information
Age 18 to 93 yrs (mean=58.08, sd=14.38)
Gender 59% male (297) and 41% female (203)
Race 73.4% white (367) and 26.6% others (126)
Diabetes mellitus 25.8% (129)
Hypertension 63% (315)
Current smoking 9% (46)
BMI (body mass index) 14.33 to 46.13 kg/m
2 (mean=25.57, sd=5.39)
Left ventricular ejection fraction 0.09 to 0.88 (mean=0.4538, sd=0.1866)
Left ventricular mass 73.88 to 835.50 g (mean=252.1, sd=94.16)
Serum sodium 117 to 147 mEq/L (mean=136.7, sd=4.52)
Hemoglobin (Hb) 6.6 to 14.6 g/dL (mean=13.06, sd=2.135)
Creatinine 0.6 to 10 mg/dL (mean=1.35, sd=0.74)
Etiology 12% Chagas (60), 28.6% Ischemic (143) and 59.4% other (297)
Other etiologies: idiopathic (n=50), hypertensive (n=143), valvular (n=76) and other (n=28); sd = standard deviation.
doi:10.1371/journal.pone.0037392.t001
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descriptive information available.
Statistical Methodology
To describe the data, descriptive statistics were calculated
(mean, median, standard deviation and frequencies) based on
information available for the 500 patients in the study. Next, the
covariates most probably associated with the survival time in days
were investigated by using the Kaplan-Meier (KM) estimator [20].
Continuous covariates were, in general, considered in two
categories based on their respective median values. The null
hypothesis of no differences between the two survival curves for
each covariate, i.e. H0:S 1(t)=S 2(t), was tested by logrank test [21].
Although the KM estimator is a useful descriptive tool, it has
not been designed to incorporate several covariates simultaneous-
ly. Hence, to evaluate the effect of a risk factor on the survival
adjusted for a set of other risk factors, we started by fitting the
proportional hazards Cox model [22], in which the hazard
function is modeled as
l(t)~l0(t)exp(X1b1z   zXpbp)~l0(t)exp(X0b), ð1Þ
where l0(t) is an arbitrary baseline hazard rate, X =( X 1,… ,X p)
are the p covariates or risk factors of interest, and b =( b1,… ,bp)’
is a p-dimensional vector of regression coefficients which is
estimated by considering the partial likelihood. Under this model,
the hazard ratio is assumed constant over time (proportional
hazards).
Covariates that change their values over time (time-dependent
covariates), such as a dynamic treatment dose, can be included in
model (1). For our data, however, covariates are not time-
dependent since they were only measured at the beginning of the
study. As the assumption of proportionality failed for some
covariates, suggesting that the risk of a patient may change over
time, even if their risk factors do not change, we next fitted an
extension of model (1) to taken into account that may exist
covariates with time-varying effects (i.e. non-proportional effects).
Under this model the hazard function is expressed on the form
l(t)~l0(t)exp(X0b(t)), ð2Þ
where the vector of regression coefficients b has been replaced by
b(t)=( b1(t), …, bp(t))’, which are functions representing the time-
varying effects of covariates over time. Parameters estimates for
this model can be obtained by considering the partial likelihood
and by the choice of smoothing parameters [23]. As estimation of
b(t) depends on smoothing methods, it is obtained by mathematical
Table 2. Logrank test performed for each covariate.
Logrank test
Covariates Statistic p-value
Age (#60 and .60 yrs) 13.00 ,0.001
Gender (male and female) 2.64 0.104
Race (white and others) 0.56 0.453
Diabetes mellitus (yes and no) 1.04 0.307
Hypertension (yes and no) 1.54 0.215
Current smoking (yes and no) 1.96 0.165
BMI (#25 and .25 kg/m2) 6.16 0.013
LV ejection fraction (,0.35 and $0.35) 10.70 0.001
LV mass (#243 and .243 g) 0.11 0.742
Serum sodium (#137 and .137 mEq/L) 27.9 ,0.001
Hemoglobin (Hb) (#13 and .13 g/dL) 15.6 ,0.001
Creatinine (#1.2 and .1.2 mg/dL) 23.4 ,0.001
Etiology (Chagas and others) 13.13 ,0.001
doi:10.1371/journal.pone.0037392.t002
Figure 1. Graphical checks of the proportional hazards assumption. A. Scaled Schoenfeld residuals against time plotted for each covariate in
the proportional hazards Cox model. B. Observed test process plotted along with 50 processes simulated for each covariate in the proportional
hazards Cox model under the hypothesis of time-invariant effects.
doi:10.1371/journal.pone.0037392.g001
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i.e. Bq(t) =
Ð t
0 bq(s)ds for q =1,…, p. The estimates of b(t) are thus
the slopes of the cumulative estimates. Tests for whether the
separate components of B(t) = (B1(t), …., Bp(t))’are constant (i.e.
H0:B q(t)=c t), as well as tests for non-significant effects (H0:B q(t)
=0), were then performed. Model (2) with some time-varying
effects and others not is termed semi-parametric multiplicative
hazards model and can be expressed as
l(t)~l0(t)exp(X0
aba(t)zX0
bbb), ð3Þ
where Xa and Xb represent the covariates with time-varying and
constant effects, respectively. From the final model, estimates of the
effects are provided and discussed. For those covariates with significant
time-varying effects, their corresponding components of Ba(t) are
shown graphically in terms of their cumulative regression estimates.
Even though model (2) or (3) appears very appealing, there are
some drawbacks related to this model as, for instance, that it is
hard to assess the uncertainty of the estimates bq(t) and also that it
is not easy to estimate the corresponding survival function
expressed as S(t)~exp({
Ð t
0 l0(s)exp(X0
aba(s)zX0
bbb)ds) not
only because we need to estimate ba(t) and bb by means of
smoothing methods, but also because it is complicated to work
with the above integral [23]. To circumvent these difficulties, the
Aalen’s additive hazards model [13–16] which allows covariates
with time-varying effects was used. Under this model, the additive
hazards are expressed as
l(t)~b0(t)zX1b1(t)z   zXp{1bp{1(t)zXpbp(t)~X0b(t) ð4Þ
where b0(t) represents the baseline hazard denoted by l0(t) in the
proportional hazards Cox model, X = (1, X1,… ,X p) is a matrix
containing a vector of ones and the p covariates (risk factors) of
interest, and b(t)=( b0(t), b1(t),…,bp(t))’is a vector of time-varying
regression coefficients. Covariates that change their values over
time (time-dependent covariates) can also be considered in model
(4). Similar to models (2) or (3), estimation and tests are based on
the cumulative effects Bq(t) =
Ð t
0 bq(s)ds (q =1,…, p). For model
(4), however, there are simple direct least squares estimators. Thus,
it can be fitted without any use of smoothing parameters. To test if
a covariate effect is time-varying or constant over time, we fitted a
variation of model (4), termed semi-parametric additive hazards
model, expressed as
l(t)~b0(t)zX1b1(t)z   zXp{1bp{1(t)zXpbp
~X0
aba(t)zX0
bbb
ð5Þ
where the effect of p 21 covariates change over time while the
effect of one of them is assumed to be constant. The matrices Xa
and Xb include the covariates with time-varying and constant
effects, respectively. To test the null hypothesis of constant effect
associated with the p-th covariate (H0: bp(t) = c or equivalently
H0: Bp(t) = c t), models (4) and (5) were compared [13].
Successive tests were performed in this stage of the analysis until
covariates with time-varying and constant effects were all
characterized. For all covariates (q =1,…, p), tests for non-
significant effects (H0: bq(t) =0 or equivalently H0: Bq(t) =0)
were also performed. Procedures for these statistical tests are
explained in details in Martinussen and Scheike [13]. From the
final model, estimates of the constant and time-varying effects were
then provided and discussed. Time-varying effects were shown
graphically in terms of their cumulative regression functions
estimates ^ B Bq(t),in which the slopes of their estimated functions
represent the coefficients bq(t). Survival function expressed for this
model as S(t)~expfX0
aBa(t){X0
btbbg is much easier to obtain
than under model (3) since it depends directly on B(t). Survival
estimated curves were shown graphically for some patients in our
study.ThepackagesurvivalavailableintheRsoftware[24]wasused
to obtain the results for model (1). Results for models (2) and (3) were
obtained in this same software using the packages timereg and coxvc
[25], as well as for models (4) and (5) using the package timereg.
Goodness-of-fit Procedures
To evaluate if the proportionality holds for each covariate in
model (1), graphics and tests based on the scaled Schoenfeld
residuals [26] were examined. No serious violation of the
proportionality assumption is observed when these residuals
plotted versus time for each covariate in the Cox model are
randomly distributed around the zero-slope line. Graphics of the
observed test-processes together with fifty simulated processes
under proportionality were also investigated. The departure
(deviation from the linear form) of the observed processes from
the simulated curves under the model indicates those covariates
having time-varying effects. Martinussen and Scheike [13] provide
further details on these procedures. The Cox-Snell residuals [27]
were also used as a way to check the overall fit of model (1). These
residuals are defined as ei~^ L L(ti)~
Ð ti
0
^ l l(s)ds for i =1,…,n, and
should look like a censored sample from a unit exponential
distribution. For a model providing a satisfactory fit to the data, a
plot of the survival probabilities of the residuals ei’s obtained by
considering the unit exponential distribution (^ S S(ei)exp) against
those obtained by the Kaplan-Meier estimator (^ S S(ei)KM), should
be roughly a straight line through the origin with slope 1. Once a
clear lack-of-fit of the proportional hazards Cox model was
observed due to the effects of some covariates being strongly time-
varying, violating the proportionality assumption, flexible alterna-
tives to Cox model like models (2) and (4), or their semi-parametric
versions (3) and (5), were used. Although additional studies are
needed to investigate more appropriate methods to assess the
goodness-of-fit of these models, here we have used procedures
based on the cumulative martingale residuals [13] as a way to
validate the fit of the models with time-varying effects to the data.
Under these procedures, cumulative martingale residuals process-
es, that will carry information about the fit of the models as a
function of each covariate, are plotted together with 50 simulated
processes under the model for evaluating if their behavior is
consistent with what should be expected under the model (zero-
mean processes). A supremum test-statistic [13] was then
computed to help summarize how serious can be a departure
from the null processes.
Table 3. Test for the proportionality in the Cox model.
Covariates Statistic p-value
Age 1.39 0.24
Serum sodium 0.47 0.49
Hemoglobin 1.08 0.30
Creatinine 3.88 0.05
a
LV ejection 2.99 0.08
a
aDepartures from the proportionality suggested for these covariates.
Tests based on the scaled Schoenfeld residuals.
doi:10.1371/journal.pone.0037392.t003
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Descriptive Statistics
Table 1 summarizes the information available for patients that
have been included in the study. Thirty-seven percent (37.6%) of
the patients have died at the end of the follow-up period. From
them, 62.8% were men and 37.2% women. Men accounted for
59.4 percent of the patients. The mean age observed was 58 years,
with the range of 18 to 93 years. About 74% were white and
90.8% were non-smoking. The prevalence of diabetes and
hypertension observed for all patients were 25.8% and 63%,
respectively. The ischemic etiology was prevalent in relation to
Chagas etiology (28.6% vs 12%) and overweight was predominant
among women (50.3% vs 47%). For left ventricular ejection
fraction the mean value was higher among women (0.51 for
females against 0.41 for males). In opposite, the mean values for
left ventricular mass, hemoglobin (Hb), and creatinine were higher
among men; 277.5 vs 216.10 g, 13.47 vs 12.47 g/dL, and 1.44 vs
1.22 mg/dL, respectively. For serum sodium, the mean values
were similar in both genders (136.6 mEq/L for males against
136.9 mEq/L for females).
In order to explore the variables usually recognized as
influencing prognosis, survival curves for each covariate were
estimated by using the Kaplan-Meier estimator. Differences
between the curves were tested by logrank test. Categorization
of continuous risk factors was done, in general, by considering two
categories of the risk factor based on its median value. Table 2
displays the results of the tests performed. At a significance level of
5%, evidence of association with the time to death was suggested
for seven of the thirteen covariates: age, body mass index (BMI),
left ventricular ejection fraction, serum sodium, hemoglobin (Hb),
creatinine, and etiology. It can also be noted that gender showed a
marginally significant association.
Although the Kaplan-Meier estimator can always be used as a
useful preliminary exploratory analysis, it is not proper to evaluate
a risk factor effect adjusted for a set of other risk factors. Thus, to
investigate the effect of each risk factor on time to death in the
presence of a set of other risk factors, as well as the possibility of
time-varying covariates effects, we next considered: (a) the
proportional hazards Cox model, (b) an extension of the Cox’s
model and (c) the additive hazards model to analyze the patients’
survival in our study. Before fitting these models, continuous
covariates were centered on their respective mean values. For each
of these models a selection strategy based on a forward stepwise
approach with the use of a probability value of #0.05 for inclusion
or deletion was used.
Proportional Hazards Cox Model
For the proportional hazards Cox model, covariates (factors)
showing significant effects were: age, serum sodium, hemoglobin
Figure 2. Cumulative coefficients obtained from the extended Cox’s model. Estimates from 1 to 750 days are for the covariates considered
in the model as having time-varying effects. Curves along with the estimates are 95% confidence limits.
doi:10.1371/journal.pone.0037392.g002
Figure 3. Cumulative coefficients obtained from the additive hazards model. Estimates from 1 to 750 days are for the covariates
considered in the model as having time-varying effects. Curves along with the estimates are 95% confidence limits.
doi:10.1371/journal.pone.0037392.g003
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etiology and gender, suggested by the preliminary analysis as
significant or marginally significant, were not significant in the
presence of other factors in the model.
For each covariate in the Cox model, Figure 1A displays the
scaled Schoenfeld residuals versus time, together with a smooth
scatter plot. The figure demonstrates evidence of deviation from
the proportionality assumption since the plotted curves are not
roughly constant over time for some covariates. Tests based on the
scaled Schoenfeld residuals shown in Table 3 also suggest
departures from the proportionality. Moreover, the observed
test-process displayed in Figure 1B for each covariate along with
50 simulated processes under the null hypothesis of time-invariant
effects, also suggest some covariates with no constant effects over
time (hemoglobin, creatinine, and left ventricular ejection
fraction). Hence, we may conclude that there is evidence of a
lack-of-fit of the proportional hazards Cox model due to the effects
of some covariates being time-varying.
Variation of Cox Model Allowing Time-varying Covariates
Effects
Under this model, significant effects were found for the same
covariates as in the proportional hazards Cox model, i.e. age,
serum sodium, Hb, creatinine, and left ventricular ejection
fraction. Evidence of time-varying effects was indicated for
hemoglobin (Hb), creatinine, and left ventricular ejection fraction
as can be seen from Figure 1B. From such figure it is relatively easy
to see departure from the zero line during the time-period for these
covariates. Creatinine, for instance, has an effect which increases
with time. From this same figure we can also see that the age and
serum sodium covariates are characterized by their time-invariant
effect since no pronounced departure from the zero line is
observed (p-values of 0.72 and 0.43, respectively). Estimates of the
effects of age and serum sodium were 0.027 (s.e. =0.00036) and
20.062 (s.e. =0.0018), respectively. Time-varying effects for
hemoglobin, creatinine, and left ventricular ejection fraction
covariates are shown in terms of their cumulative regression
estimates in Figure 2.
Table 4. Tests associated with the additive hazards model.
Test for non-significant effect Test for time-invariant effects
Covariates Statistics p-value Statistics p-value
Intercept 10.70 ,0.001 0.162 0.001
Age 2.85 0.048 0.004 0.291
a
Serum sodium 3.33 0.018 0.017 0.199
a
Hemoglobin 3.27 0.026 0.044 0.013
Creatinine 3.43 0.013 0.221 0.003
LV ejection fraction 3.88 0.001 0.502 0.007
aTime-invariant effects suggested for age and serum sodium (p.0.05).
All covariates were centered in their respective mean values.
doi:10.1371/journal.pone.0037392.t004
Figure 4. Graphical checks of the overall fit of the Cox model. A. Survival probabilities obtained from the Cox-Snell residuals by considering
the unit exponential distribution and the Kaplan-Meier estimator. B. Survival curves obtained from the Cox-Snell residuals by considering the Kaplan-
Meier estimator and the unit exponential distribution.
doi:10.1371/journal.pone.0037392.g004
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The covariates (factors) showing significant effects in the final
additive hazards model were also: age, serum sodium, Hb,
creatinine, and left ventricular ejection fraction. Evidence of time-
varying effects was indicated for three of the selected factors (Hb,
creatinine, and left ventricular ejection fraction). In agreement
with the Cox model with time-varying effects, the impact of age
and serum sodium was characterized by their constant effects over
time. Note from Figure 3 that the cumulative regression
coefficients associated with factors that were identified as having
time-varying effects seem to change with time given that the
cumulative does not seem to be a straight line as should be
expected in case of time-invariant effects. The intercept curve
corresponds to the cumulative hazard function for a patient with
mean values of Hb, creatinine and LV ejection fraction. Table 4
displays the results of some tests related to the effects remaining in
the final model. From them, it is possible to see that the covariates
age and serum sodium showed time-invariant effects (p-values
.0.15). Estimates of their effects were 1.6e
25 (s.e. =6.1e
26) and
28.5e
25 (s.e. =2.7e
25), respectively.
Checking the Goodness-of-fit of the Models
In order to assess if the fitted models provide an adequate fit to
the data, one can use the Cox-Snell residuals for the proportional
hazards Cox model and procedures based on martingale residuals
[13] for the two time-varying regression models. From graphical
analysis of the Cox-Snell residuals displayed in Figures 4A and 4B
a moderate deviation from the unit exponential distribution can be
observed, indicating that the Cox model presents a not too
adequate fit to the data. On the other hand, the cumulative
martingale residuals displayed in Figure 5A together with 50
simulated processes under the extended Cox model, suggest that
all covariates have a behavior consistent with this model (zero-
mean martingales). This is supported by the p-values of the
supremum test-statistic shown in Table 5. Similar plots displayed
in Figure 5B for the semi-parametric additive model indicate that
the behavior of the residuals for the covariate sodium is not too
consistent with this model (also supported by the supremum test-
statistic shown in Table 5). In Figure 6 one can directly compare
the different survival curves predicted from the models for two
distinct clinical scenarios. In addition, a direct comparison with
empirical data can be obtained by comparing the survival curves
predicted from the models with the non-parametric Kaplan-Meier
curves. Under the first clinical scenario (Figure 6A), no serious
discrepancies can be observed between the non-parametric and
model-based survival curves. But, in the second scenario
(Figure 6B) survival predictions obtained particularly from the
Cox model are quite different from those obtained by the Kaplan-
Meier estimator. Although the considered models have difficulty to
accommodate the heart failure dataset well, the additive modeling
suggests to be slight better than the standard Cox and the
extended Cox ones (Figure 6B), but none of them fit the data very
well. Since from the 500 patients under study 188 died during the
follow up, a possibility that one could think to enrich or enhance
the overall goodness of fit is to consider models that accommodate
the presence of long-term survivals. In this case, however, an
aspect that must be taken into consideration is whether follow up
in the data is sufficient [28]. In our study a longer follow up seems
to be recommended since at the last follow-up time there were
about 30% of patients with less than five years of follow-up and
also about 15% who did not return.
Figure 5. Cumulative martingale residuals plotted for each covariate. A. Cumulative residuals from the Coxs model with time-varying
effects. B. Cumulative residuals from the additive hazards model with time-varying effects.
doi:10.1371/journal.pone.0037392.g005
Table 5. Tests for assessing covariates consistent with the
extended models.
Extended Cox model Extended Additive model
Covariates
Sup
|hat B(t)|
p-
value sup|hat B(t)| p-value
Age 5.34 0.87 6.14 0.61
Serum sodium 7.20 0.59 10.24 0.06
Hemoglobin 6.01 0.79 7.79 0.22
Creatinine 4.53 0.91 5.90 0.67
LV ejection 9.39 0.41 7.28 0.33
Supremum test-statistic was based on the cumulative martingale residuals.
doi:10.1371/journal.pone.0037392.t005
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Studies where the response is the time from a well defined
moment in time to the occurrence of some event of interest are
usual in many research areas. For handling these kinds of data
several methods have been proposed in the last decades. Amongst
them, are most known the non-parametric estimator proposed by
Kaplan and Meier [20] and the proportional hazards Cox model
[22], which assumes proportionality of the hazards. This
assumption, however, may not be proper in some applications
and there is the need for alternative models consider time-varying
effects of their covariates.
Interestingly, from analyses performed in this paper, particularly
on the scaled Schoenfeld residuals associated to the proportional
hazards Cox model, we found evidence that suggested three of the
most important predictors of outcomes in patients with heart
failure (hemoglobin, creatinine and left ventricular ejection
fraction) as having time-varying effects (Figures 1A, 1B and
Table 3), meaning that the effects of such covariates are probably
not constant over time, violating thus the assumption of
proportional hazards. Although the time-varying effects observed
in this cohort might not hold true in other populations, this brings
into discussion whether scores derived from a Cox model
framework without time-varying effects will be able to describe
noticeable and important features of the data sufficiently well, or,
put into a different perspective, whether using a Cox proportional
hazards framework is the most competitive approach to derive
proxy data that emulate the clinical scenario of heart failure, and
that may be used for clinical prognostication and important
treatment decisions.
In order to take into account time-varying effects, here we have
used flexible variations of the Cox model and also of the Aalen
additive hazards model in which some of the covariates are
allowed to change over time while others not. These models
provide alternative summary measures of the data, especially when
the follow-up period is long, as in the present study, or in cancer
studies, since part of the observed rate l(t) is explained by the
natural mortality of the background population. The covariates
considered were only the best predictors of mortality in patients
with heart failure, but the use of other predictors can be
incorporated in future models.
Although methodological limitations have been found in this
work with regard to appropriate methods for assessing the
goodness of fit of the models evaluated, the results of our analyses
were able to suggest that models do offer rather different survival
estimates that could, in a clinical setting, provide significantly
different thresholds for very expensive treatment options like heart
transplantation, ventricular assist-device implantation, or ICD use.
Predicted survival derived from these models are specially
discordant from the proportional hazards Cox model (but not
necessarily from empirically observed mortality) when one is more
concerned with long follow-up times (see Figures 5 and 6), and
specially for subgroups of patients that have values for time-
varying variables that are distant from the mean values observed in
the sample used for model derivation (see Figures 6A and 6B).
Clinical predictions (prognostic assessments) are usually based
on a patients status (covariates) at the time of evaluation. Although
there are alternatives to model covariate’s change over time or
even to recalculate scores after changes in clinical status or
medications/devices are prescribed, it isn’t always practical to take
historical or future values of some covariates into account. The use
of the described models may permit that, at baseline, one can
account for the greater tendency of particular covariates to
dynamically change.
Although we have graphically suggested better fit of the time-
varying effects models over the standard Cox model, one of the
limitations of the present work is the lack of validated analytical
procedures to compare these different models in terms of their
overall prediction capacity. In the paper we have used procedures
based on the Cox-Snell and martingale residuals as a way to show
that the models with time-varying effects can produce better
goodness-of-fit than the proportional hazards Cox model since this
model did not capture all important aspects of the data analyzed.
One such alternative could perhaps be the Bayesian information
Figure 6. Non-parametric and model-based survival curves for two scenarios. A. Curves predicted for patients with mean values for all
covariates (mean values in Table 1). B. Curves predicted for hypothetical patients aged 32 yrs old, serum sodium =137, Hb =13.7, creatinine =1.0
and LV ejection fraction =0.37. A subset of 39 patients who provided mean values equal to those considered in this scenario was used to estimate
the Kaplan-Meier curve.
doi:10.1371/journal.pone.0037392.g006
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model, Volinsky and Raftery [29] propose defining BIC in terms
of the maximized partial likelihood using the number of deaths
rather than the number of individuals in the BIC penalty term,
BIC has not yet been addressed for survival models with time-
varying covariate effects like those used in this paper for analyzing
the heart failure data. Therefore, additional studies are needed to
investigate more appropriate methods to assess the goodness-of-fit
of these models. Indeed, we consider this to be an analytical
problem that should deserve more attention.
In conclusion, the analyses performed suggest that the extended
Cox model and also variations of the additive hazards model are
valuable tools for identifying covariates with time-varying effects
present in the heart failure models. The implementation of time-
varying covariate effects into heart failure prognostication models
may reduce bias and increase the specificity of such models, thus
contributing to more cost-effective management of patients with
such condition.
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